This approach has both clinical and operational benefits: the UCART is designed to have a lymphodepleting effect, and the CAR T-cell cross reaction is suppressed, allowing for successful manufacturing.
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART).
Sourdive, Executive Vice President Corporate Development, Cellectis, stated: The manufacturing campaign for UCART123 consolidates Cellectis GMP processes and our expertise in its industrialization while allowing Cellectis to further enhance and improve the manufacturing of its UCART
Cellectis, a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) and CELLforCURE, the largest commercial industrial facility for the production of innovative therapeutic cell therapies in Europe, a subsidiary of the biopharmaceutical group LFB, announce that they have entered into an agreement for the cGMP manufacturing of clinical batches of Cellectis allogeneic CART cells.
Pursuant to this agreement, CELLforCURE will be responsible for the manufacturing of cGMP clinical batches for candidates from Cellectis UCART product family.